An interventional study of Early Diagnostic Response Model Expanded in Autism Spectrum Disorder and Autism, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged 16 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Emory University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Autistic Disorder by Emory University — 5 open to participants now, 5 under way, none of them phase 3. Autistic Disorder · Emory University.
Among the 10 studies in Autistic Disorder by Emory University, this one is one of 2 that started in 2026, is one of 8 with no phase, and was the 9th registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →5 of the 10 studies in Autistic Disorder by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Healthy volunteers
Emory University · Sites in United States
Ages 8 mo–10 mo · Healthy volunteers
Emory University · Sites in United States
Ages 16 mo–36 mo
Emory University · Sites in United States
Ages 18–24
By country, each count listing its studies:
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 16 Months to 36 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 100 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 51 across the 9 interventional studies, 2,120 across the 1 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
2 of the studies in Autistic Disorder by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07623759Emory UniversityEarly Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program | 2027-06 |
| NCT07859306Emory UniversityEvaluating the Feasibility of Collecting User Interaction Data at the Emory Autism Center Using MapHabit Software | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Autistic Disorder by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study includes children identified as moderate- as well as high-risk for autism spectrum disorder (ASD) within Georgia's Babies Can't Wait (BCW) Early Intervention (EI) program. The project will evaluate the feasibility, acceptability, and implementation of a diagnostic protocol, including optional measures, through measures of recruitment, retention, adherence, provider confidence, and time from referral to report completion. It will also examine which child diagnostic measures are essential and needed to improve psychologists' diagnostic confidence. Caregiver, early intervention provider, and clinician experiences and satisfaction before, during, and after assessment will be assessed to evaluate protocol acceptability, knowledge, and access to services. Outcomes will be analyzed using the RE-AIM Framework (reach, effectiveness, adoption, implementation, maintenance) and compared across BCW districts and child characteristics, including changes in autism screening, referral, and evaluation rates over time.
The objective of this study is to develop, pilot, and evaluate a telehealth diagnostic protocol for assessing toddlers identified as moderate- or high-risk for autism spectrum disorder (ASD) within Georgia's Babies Can't Wait (BCW) Early Intervention (EI) program.
Many BCW children with moderate- or high-risk screening results face long wait times and limited access to diagnostic evaluations. This pilot will evaluate how many of these assessments can be completed entirely via a streamlined telehealth protocol and the level of diagnostic confidence achieved. It is hypothesized that the EDRM-E will increase access to timely, evidence-based autism evaluations and yield diagnostic outcomes comparable to in-person assessments based on DSM-5-TR criteria.
Secondary aims include identifying which additional assessment measures increase clinician confidence and are most acceptable to families and providers. It is hypothesized that moderate-risk children will require more in-depth evaluation and that families receiving expanded assessments will report higher satisfaction and acceptability.
A further objective is to examine family, BCW provider, and clinician satisfaction, understanding, and access to services following participation in the EDRM-E pilot. No data will be submitted to the FDA, and no algorithm, product, or software will be commercialized or used outside Emory.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Post-consent, families with children between 16-33 months will receive a link to complete the EAC Developmental History Survey on REDCap and a link to complete parent/caregiver questionnaires about developmental and/or adaptive information. Children will be assessed via a remote telehealth session with an EAC clinician, using age-appropriate standardized measures. Clinicians rate confidence after four points: intake review, parent interview and child observation, child assessment, and DSM-5-TR checklist completion. Feedback is provided via telehealth, and a final report with recommendations is issued. Psychologists will be asked about the protocol after each assessment. Parents/caregivers will be asked to answer questions during the assessment, immediately after the assessment, and 3 months later. EI providers will also be asked questions about their experience after the assessment. Total length of enrollment range 3-16 weeks.
Behavioral: Early Diagnostic Response Model Expanded
A telehealth diagnostic protocol for assessing toddlers identified as moderate- or high-risk for autism spectrum disorder (ASD) within Georgia's Babies Can't Wait (BCW) Early Intervention (EI) program. This pilot will evaluate how many of the initial assessments can be completed entirely via a streamlined telehealth protocol and the level of diagnostic confidence achieved.
Also known as: EDRM-E
Number of moderate and high-risk referral assessments that were completed entirely via a streamlined telehealth protocol
Number of moderate and high-risk referral assessments that can be completed entirely via streamlined telehealth protocol
Time frame: Monthly until the end of the study (approximately one year)
Number of participants referred to the Early Diagnostic Response Model Expanded (EDRM-E)
Monthly numbers of high-risk referrals to the EDRM-E pilot project and total number of referrals made to the EDRM-E at the end of the study.
Time frame: End of study (up to 16 weeks post-intervention)
Number of participants consented in the Early Diagnostic Response Model Expanded (EDRM-E) study
Monthly number of families referred who consent to EDRM-E participation
Time frame: Monthly until the end of the study (approximately one year)
Response rate in the Early Diagnostic Response Model Expanded (EDRM-E) study
Response rate will be calculated at project end using the formula \[# of families who consented / # of families referred to project\] x 100 = response rate)
Time frame: Monthly until the end of the study (approximately one year)
Number of participants that completed the Early Diagnostic Response Model Expanded (EDRM-E) study
Quarterly numbers of participants that completed the EDRM-E assessment protocol and total number of participants who completed EDRM-E assessment protocol at study conclusion
Time frame: Every 3 months (Quarterly) until end of study (approximately one year)
Time from referral to completion of the program
Individual calculation of time from BCW referral to final summary report sent to family using the formula: Date of Final Report sent to family - Date of referral from BCW =Time in EDRM-E pilot
Time frame: Up to 12 weeks post-intervention
Number of moderate and high-risk referrals by BCW district
Number of moderate-high risk referral assessments by specific BCW district. Monthly, Quarterly, and Total numbers of participants who completed EDRM-E pilot assessment.
Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
Number of moderate and high-risk referral by child factors
Number of high-risk referral assessments by child factors. Monthly, Quarterly, and Total numbers of participants who completed EDRM-E pilot assessment.
Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
Number of moderate and high-risk referrals by clinician setting
Number of high-risk referral assessments by clinician setting. Monthly, Quarterly, and Total numbers of participants who completed EDRM-E pilot assessment.
Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
Number of participants with additional information collected to make a final DSM-5 conclusion
Number of participants with additional information collected to make a final DSM-5 conclusion
Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
Parent satisfaction of EDRM-E assessment survey
Administered at the end of individual EDRM-E assessment. Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM project. Total score: 0 to 110.
Time frame: At completion of EDRM-E assessment (4 weeks post-intervention)
BCW provider(s) Service Coordinator satisfaction with EDRM-E assessment survey
Administered at end of individual EDRM-E assessment. Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM-E project.
Time frame: At completion of EDRM-E assessment (4 weeks post-intervention)
Parent satisfaction with access to treatment survey
Parent satisfaction with access to treatment survey Administered 3-months after completion of EDRM-E assessment. Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM-E project. Total score: 0 to 15.
Time frame: 3 months after completion of EDRM-E assessment
BCW provider(s) Early Intervention Coordinator satisfaction with EDRM-E pilot survey
Completed every 3 months (Quarterly). Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM project. Total score: 0 to 55
Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks postintervention
Number of families screened moderate and high-risk for ASD and referred for an evaluation
Number of families screened moderate and high-risk for ASD and referred for an evaluation
Time frame: Through study completion, an average of 1 year
Number of families who received ASD evaluation by the end of the study through the pilot versus other means
Number of families who received ASD evaluation by the end of the study through the pilot versus other means
Time frame: Through study completion, an average of 1 year
Plan to share: Yes — Data will be shared with qualified researchers with relevant expertise, researchers affiliated with academic or clinical institutions, and investigators with IRB/ethics approval for secondary analyses as needed, including basic demographic information, scores on assessments, and final diagnostic results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Proposals may be submitted to up to 3 years following article publication. After 3 years, data will be provided in Emory University's data warehouse but without investigator support other than deposited materials.
Access criteria: Researchers who provide a methodologically sound proposal that has been approved by an IRB. To achieve aims in proposed activity and/or for meta-analysis of telehealth assessments.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 12 months is below that.
Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.